NASDAQ:TECH - Bio-Techne Stock Price, Price Target & More

$152.78 +0.59 (+0.39 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$152.78

Today's Range$151.37 - $153.87

52-Week Range$99.96 - $154.55

Volume208,222 shs

Average Volume150,164 shs

Market Capitalization$5.70 billion

P/E Ratio44.67

Dividend Yield0.84%

Beta0.7

About Bio-Techne (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryLife Sciences Tools & Services

SectorMedical

SymbolNASDAQ:TECH

CUSIP87837710

Webwww.techne-corp.com

Phone612-379-8854

Debt

Debt-to-Equity Ratio0.36%

Current Ratio3.10%

Quick Ratio2.49%

Price-To-Earnings

Trailing P/E Ratio44.67

Forward P/E Ratio38.10

P/E Growth2.53

Sales & Book Value

Annual Sales$563 million

Price / Sales10.17

Cash Flow$5.0656 per share

Price / Cash30.16

Book Value$25.44 per share

Price / Book6.01

Profitability

EPS (Most Recent Fiscal Year)$3.42

Net Income$76.08 million

Net Margins19.17%

Return on Equity14.39%

Return on Assets8.89%

Miscellaneous

Employees1,800

Outstanding Shares37,470,000

How to Become a New Pot Stock Millionaire

Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Wednesday, February 7th. Shareholders of record on Friday, February 16th will be given a dividend of $0.32 per share on Friday, March 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date of this dividend is Thursday, February 15th. View Bio-Techne's Dividend History.

How were Bio-Techne's earnings last quarter?

Bio-Techne (NASDAQ:TECH) posted its quarterly earnings data on Tuesday, February, 6th. The biotechnology company reported $1.02 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.92 by $0.10. The biotechnology company earned $154.15 million during the quarter, compared to the consensus estimate of $145.93 million. Bio-Techne had a return on equity of 14.39% and a net margin of 19.17%. The business's revenue was up 16.9% on a year-over-year basis. During the same period last year, the firm posted $0.81 earnings per share. View Bio-Techne's Earnings History.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Bio-Techne.

What price target have analysts set for TECH?

6 Wall Street analysts have issued 1 year price targets for Bio-Techne's stock. Their predictions range from $115.00 to $163.00. On average, they expect Bio-Techne's stock price to reach $148.75 in the next year. View Analyst Ratings for Bio-Techne.

Who are some of Bio-Techne's key competitors?

Some companies that are related to Bio-Techne include bluebird bio (BLUE), Seattle Genetics (SGEN), AveXis (AVXS), Neurocrine Biosciences (NBIX), Spark Therapeutics (ONCE), China Biologic Products (CBPO), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA) and Audentes Therapeutics (BOLD).

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the folowing people:

Mr. Charles R. Kummeth, Pres, CEO & Director (Age 58)
Mr. James T. Hippel, Sr. VP of Fin., CFO & Principal Accounting Officer (Age 47)
Mr. N. David Eansor, Sr. VP of Biotechnology Division (Age 57)
Mr. Robert M. Gavin, Sr. VP of Protein Platforms Division (Age 50)
Mr. Kevin S. Gould, Sr. VP of Diagnostics Division (Age 52)

Has Bio-Techne been receiving favorable news coverage?

Media coverage about TECH stock has been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bio-Techne earned a media sentiment score of 0.16 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.83 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $152.78.

How big of a company is Bio-Techne?

Bio-Techne has a market capitalization of $5.70 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $3.42 on an earnings per share basis. Bio-Techne employs 1,800 workers across the globe.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]

MarketBeat Community Rating for Bio-Techne (TECH)

Community Ranking:		2.2 out of 5 ( )
Outperform Votes:		171 (Vote Outperform)
Underperform Votes:		209 (Vote Underperform)
Total Votes:		380

MarketBeat's community ratings are surveys of what our community members think about Bio-Techne and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Bio-Techne (NASDAQ:TECH) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Bio-Techne in the last 12 months. Their average twelve-month price target is $148.75, suggesting that the stock has a possible downside of 2.64%. The high price target for TECH is $163.00 and the low price target for TECH is $115.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.83	2.71	2.67	2.60
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$148.75	$148.75	$138.00	$126.3333
Price Target Upside:	2.64% downside	5.24% upside	1.44% downside	3.69% upside

Bio-Techne (NASDAQ:TECH) Consensus Price Target History

Price Target History for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/1/2018	Deutsche Bank	Set Price Target	Buy -> Buy	$154.00 -> $163.00	Low
2/7/2018	Craig Hallum	Reiterated Rating	Buy	$140.00 -> $160.00	Medium
2/7/2018	Robert W. Baird	Boost Price Target	Outperform -> Outperform	$154.00 -> $157.00	Medium
12/5/2017	Leerink Swann	Reiterated Rating	Buy		Medium
10/24/2017	Citigroup	Reiterated Rating	Buy	$125.00 -> $115.00	N/A
7/13/2017	Wells Fargo	Initiated Coverage	Market Perform -> Market Perform		Low
3/27/2017	Janney Montgomery Scott	Downgrade	Buy -> Neutral		High

(Data available from 4/21/2016 forward)

Bio-Techne (NASDAQ:TECH) Earnings History and Estimates Chart

Earnings by Quarter for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) Earnings Estimates

2018 EPS Consensus Estimate: $3.92
2019 EPS Consensus Estimate: $4.37

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.88	$0.88	$0.88
Q2 2018	2	$0.84	$0.88	$0.86
Q3 2018	2	$0.96	$1.09	$1.03
Q4 2018	2	$1.09	$1.21	$1.15
Q1 2019	2	$0.89	$1.02	$0.96
Q2 2019	2	$0.92	$1.11	$1.02
Q3 2019	2	$1.04	$1.24	$1.14
Q4 2019	2	$1.18	$1.33	$1.26

Bio-Techne (NASDAQ TECH) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		$1.12					N/A
2/6/2018	Q2 2018	$0.92	$1.02	$145.93 million	$154.15 million	View	Listen
10/31/2017	Q1 2018	$0.82	$0.90	$142.37 million	$144.61 million	View	N/A
8/8/2017	Q4 2017	$0.99	$1.09	$150.25 million	$156.60 million	View	Listen
5/2/2017	Q3 2017	$0.93	$0.97	$142.83 million	$144.04 million	View	Listen
2/7/2017	Q217	$0.85	$0.81	$134.74 million	$131.80 million	View	Listen
10/31/2016	Q117	$0.79	$0.84	$127.47 million	$130.60 million	View	Listen
8/17/2016	Q416	$0.96	$0.92	$129.23 million	$134.80 million	View	Listen
5/3/2016	Q316	$0.89	$1.01	$122.65 million	$131.00 million	View	N/A
2/2/2016	Q216	$0.82	$0.88	$118.59 million	$120.90 million	View	N/A
10/28/2015	Q1	$0.85	$0.79	$116.91 million	$12.40 million	View	Listen
8/6/2015	Q415	$0.86	$0.87	$116.85 million	$117.70 million	View	N/A
5/5/2015	Q315	$0.91	$0.86	$119.30 million	$114.20 million	View	N/A
2/3/2015	Q215	$0.86	$0.89	$112.73 million	$111.90 million	View	N/A
10/28/2014	Q115	$0.87	$0.85	$108.65 million	$108.50 million	View	N/A
8/11/2014	Q414	$0.85	$0.88	$91.80 million	$92.50 million	View	N/A
4/28/2014	Q314	$0.89	$0.94	$92.50 million	$95.60 million	View	N/A
2/4/2014	Q214	$0.80	$0.75	$84.79 million	$84.00 million	View	N/A
10/29/2013	Q114	$0.80	$0.83	$82.36 million	$85.70 million	View	N/A
8/6/2013	Q4 2013	$0.83	$0.82	$79.71 million	$79.50 million	View	N/A
4/30/2013	Q3 2013	$0.90	$0.88	$84.00 million	$81.00 million	View	N/A
2/5/2013	Q2 2013	$0.77	$0.74	$76.40 million	$75.10 million	View	N/A
10/23/2012		$0.79	$0.75			View	N/A
7/31/2012		$0.85	$0.80			View	N/A
5/1/2012		$0.89	$0.90			View	N/A
1/31/2012		$0.79	$0.76			View	N/A
10/25/2011		$0.84	$0.81			View	N/A
8/2/2011		$0.76	$0.76			View	N/A
5/3/2011		$0.80	$0.84			View	N/A
2/1/2011		$0.68	$0.71			View	N/A
10/26/2010	Q1 2011	$0.73	$0.71			View	N/A
8/3/2010	Q4 2010	$0.71	$0.69			View	N/A
5/4/2010	Q3 2010	$0.79	$0.87			View	N/A
2/2/2010	Q2 2010	$0.68	$0.66			View	N/A
10/28/2009	Q1 2010	$0.70	$0.72			View	N/A
8/4/2009	Q4 2009	$0.69	$0.68			View	N/A
4/28/2009	Q3 2009	$0.72	$0.74			View	N/A
2/3/2009	Q2 2009	$0.64	$0.62			View	N/A
10/22/2008	Q1 2009	$0.66	$0.74			View	N/A
8/5/2008	Q4 2008	$0.67	$0.70			View	N/A
4/29/2008	Q3 2008	$0.66	$0.76			View	N/A
1/29/2008	Q2 2008	$0.54	$0.60			View	N/A

(Earnings results data provided by Zacks Investment Research)

Bio-Techne (NASDAQ:TECH) Dividend Information

Bio-Techne pays an annual dividend of $1.28 per share, with a dividend yield of 0.84%. TECH's most recent quarterly dividend payment was Friday, March 2. Bio-Techne pays out 37.43% of its earnings out as a dividend.

Most Recent Dividend:	3/2/2018
Annual Dividend:	$1.28
Dividend Yield:	0.84%
Payout Ratio:	37.43% (Trailing 12 Months of Earnings) 31.92% (Based on This Year's Estimates) 27.83% (Based on Next Year's Estimates)

Dividend Payments by Quarter for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/7/2018	quarterly	$0.32	0.94%	2/15/2018	2/16/2018	3/2/2018
10/31/2017	Quarterly	$0.32	1%	11/9/2017	11/10/2017	11/24/2017
8/9/2017	Quarterly	$0.32	1.1%	8/16/2017	8/18/2017	9/1/2017
5/2/2017	quarterly	$0.32	1.15%	5/17/2017	5/19/2017	6/2/2017
2/7/2017	quarterly	$0.32	1.27%	2/15/2017	2/17/2017	3/3/2017
11/1/2016	Quarterly	$0.32		11/9/2016	11/14/2016	11/28/2016
8/17/2016	quarterly	$0.32		8/25/2016	8/29/2016	9/12/2016
5/3/2016	quarterly	$0.32	1.27%	5/11/2016	5/13/2016	5/27/2016
2/2/2016	quarterly	$0.32	1.48%	2/10/2016	2/12/2016	2/26/2016
10/29/2015	quarterly	$0.32	1.45%	11/10/2015	11/13/2015	11/27/2015
8/6/2015	quarterly	$0.32	1.18%	8/13/2015	8/17/2015	8/28/2015
5/5/2015	quarterly	$0.32	1.31%	5/11/2015	5/15/2015	5/29/2015
2/3/2015	quarterly	$0.32	1.4%	2/11/2015	2/13/2015	2/27/2015
10/30/2014	quarterly	$0.32	1.41%	11/6/2014	11/10/2014	11/24/2014
8/11/2014	quarterly	$0.31	1.31%	8/19/2014	8/21/2014	8/29/2014
4/28/2014	quarterly	$0.31	1.37%	5/7/2014	5/9/2014	5/23/2014
2/4/2014	quarterly	$0.31	1.48%	2/12/2014	2/14/2014	2/28/2014
10/31/2013	quarterly	$0.31	1.4%	11/7/2013	11/12/2013	11/25/2013
8/6/2013	quarterly	$0.30	1.62%	8/14/2013	8/16/2013	8/31/2013
4/30/2013	quarterly	$0.30	1.86%	5/8/2013	5/10/2013	5/24/2013
2/5/2013	quarterly	$0.30	1.74%	2/13/2013	2/15/2013	3/1/2013

(Data available from 1/1/2013 forward)

Bio-Techne (NASDAQ TECH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 97.14%

Insider Trading History for Bio-Techne (NASDAQ:TECH)

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ TECH) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2018	Charles A Dinarello	Director	Sell	5,000	$136.06	$680,300.00
11/1/2017	Robert V Baumgartner	Director	Sell	5,000	$130.18	$650,900.00	12,712
10/10/2017	Roger C Lucas	Director	Sell	100	$121.96	$12,196.00
9/8/2017	Roger C Lucas	Director	Sell	100	$120.94	$12,094.00	1,970
9/6/2017	Karen A Holbrook	Director	Sell	1,059	$121.73	$128,912.07	914
8/10/2017	Roger C Lucas	Director	Sell	100	$114.30	$11,430.00	2,070
7/10/2017	Roger C Lucas	Director	Sell	100	$116.86	$11,686.00	2,170
6/9/2017	Roger C Lucas	Director	Sell	100	$113.62	$11,362.00	2,270
5/31/2017	Charles A Dinarello	Director	Sell	5,000	$111.37	$556,850.00	12,473
5/25/2017	Karen A Holbrook	Director	Sell	5,000	$111.15	$555,750.00	6,973
5/10/2017	Roger C Lucas	Director	Sell	100	$110.59	$11,059.00	3,429
4/10/2017	Roger C Lucas	Director	Sell	100	$101.15	$10,115.00	3,529
1/10/2017	Roger C Lucas	Director	Sell	100	$103.57	$10,357.00	3,829
11/29/2016	Karen A Holbrook	Director	Sell	1,000	$106.73	$106,730.00	1,973
11/16/2016	Roger C Lucas	Director	Sell	100	$105.75	$10,575.00	4,029
9/21/2016	Roger C Lucas	Director	Sell	100	$108.91	$10,891.00	3,315
9/8/2016	John L Higgins	Director	Sell	1,700	$109.83	$186,711.00	1,359
9/8/2016	Kevin S. Gould	SVP	Sell	524	$110.50	$57,902.00
9/2/2016	Robert V Baumgartner	Director	Sell	6,467	$107.17	$693,068.39	8,446
8/24/2016	Robert V Baumgartner	Director	Sell	3,533	$107.10	$378,384.30	9,592
8/17/2016	Roger C. Lucas	Director	Sell	100	$113.70	$11,370.00
7/20/2016	Roger C Lucas	Director	Sell	100	$111.03	$11,103.00	3,615
6/15/2016	Roger C Lucas	Director	Sell	100	$112.15	$11,215.00	3,715
5/18/2016	Roger C Lucas	Director	Sell	100	$102.53	$10,253.00	3,815
5/9/2016	Charles A Dinarello	Director	Sell	5,000	$101.91	$509,550.00	6,559
5/6/2016	Roger C Lucas	Director	Sell	500	$100.24	$50,120.00	3,915
4/20/2016	Roger C Lucas	Director	Sell	100	$92.40	$9,240.00	4,315
3/16/2016	Roger C Lucas	Director	Sell	100	$92.90	$9,290.00	4,415
2/5/2016	Roger C. Lucas	Director	Sell	5,000	$83.68	$418,400.00	4,515
8/13/2015	Roger C Lucas	Director	Sell	5,000	$106.01	$530,050.00
6/8/2015	Randolph C Steer	Director	Sell	1,000	$99.39	$99,390.00
2/19/2015	Howard V Oconnell	Director	Sell	5,000	$95.78	$478,900.00
12/10/2014	Karen A Holbrook	Director	Sell	1,000	$92.40	$92,400.00
12/9/2014	Kevin J Reagan	VP	Sell	3,591	$89.35	$320,855.85
12/8/2014	Charles A Dinarello	Director	Sell	3,000	$90.44	$271,320.00
8/14/2014	Karen A Holbrook	Director	Sell	5,000	$95.54	$477,700.00
5/7/2014	Howard Oconnell	Director	Sell	5,000	$91.00	$455,000.00	1,000
3/4/2014	Karen Holbrook	Director	Sell	5,000	$89.83	$449,150.00	1,000
2/27/2014	Randolph Steer	Director	Sell	5,000	$88.78	$443,900.00	1,000
11/13/2013	Randolph Steer	Director	Sell	15,000	$86.20	$1,293,000.00	1,000
11/8/2013	Robert Baumgartner	Director	Sell	10,000	$87.00	$870,000.00	4,000
11/4/2013	Roger C Lucas	Director	Sell	10,000	$87.64	$876,400.00
5/6/2013	Howard V Oconnell	Director	Buy	2,361	$65.00	$153,465.00

(Data available from 1/1/2013 forward)

Bio-Techne (NASDAQ TECH) News Headlines

Source:

Date	Headline
	Bio-Techne (TECH) Coverage Initiated at Wells Fargo www.americanbankingnews.com - April 18 at 1:56 PM
	Analyzing Bio-Techne (TECH) & Osiris Therapeutics (OSIR) www.americanbankingnews.com - April 16 at 7:07 PM
	$164.72 Million in Sales Expected for Bio-Techne (TECH) This Quarter www.americanbankingnews.com - April 14 at 3:51 AM
	Analysts Anticipate Bio-Techne (TECH) Will Announce Earnings of $1.14 Per Share www.americanbankingnews.com - April 12 at 11:21 AM
	BIO-TECHNE (TECH) Downgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - April 5 at 10:14 PM
	BIO-TECHNE (TECH) Given Buy Rating at Citigroup www.americanbankingnews.com - April 5 at 10:14 PM
	BIO-TECHNE Corp (TECH) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - April 4 at 10:05 AM
	BIO-TECHNE (TECH) Upgraded to Buy at ValuEngine www.americanbankingnews.com - April 2 at 11:26 PM
	BIO-TECHNE (TECH) Upgraded to "Buy" at BidaskClub www.americanbankingnews.com - March 29 at 3:01 PM
	Analysts Anticipate BIO-TECHNE Corp (TECH) Will Post Quarterly Sales of $164.10 Million www.americanbankingnews.com - March 28 at 8:09 AM
	Brokerages Anticipate BIO-TECHNE Corp (TECH) to Announce $1.15 EPS www.americanbankingnews.com - March 26 at 11:14 AM
	3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH) www.zacks.com - March 22 at 9:25 AM
	Bio-Techne Expands RNAscope® ISH Automation - Facilitating Drug Discovery and Development www.prnewswire.com - March 21 at 1:24 PM
	BidaskClub Upgrades BIO-TECHNE (TECH) to "Strong-Buy" www.americanbankingnews.com - March 16 at 10:28 PM
	10 Growth Stocks for Long-Term Investors finance.yahoo.com - March 15 at 9:04 AM
	Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract finance.yahoo.com - March 14 at 6:02 PM
	BIO-TECHNE Corp (TECH) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - March 10 at 7:36 AM
	BIO-TECHNE Corp (TECH) Expected to Post Earnings of $1.15 Per Share www.americanbankingnews.com - March 9 at 5:58 AM
	BIO-TECHNE Corp (TECH) Stake Decreased by Bank of New York Mellon Corp www.americanbankingnews.com - March 6 at 4:54 AM
	BIO-TECHNE Corp (TECH) Shares Bought by Arizona State Retirement System www.americanbankingnews.com - March 3 at 4:22 AM
	The Manufacturers Life Insurance Company Grows Position in BIO-TECHNE Corp (TECH) www.americanbankingnews.com - March 2 at 7:38 PM
	BIO-TECHNE Corp (TECH) Position Raised by Snyder Capital Management L P www.americanbankingnews.com - March 2 at 1:56 PM
	Mackenzie Financial Corp Sells 143,295 Shares of BIO-TECHNE Corp (TECH) www.americanbankingnews.com - March 2 at 1:37 PM
	BIO-TECHNE Corp (TECH) Shares Bought by California Public Employees Retirement System www.americanbankingnews.com - March 2 at 5:21 AM
	BIO-TECHNE (TECH) PT Set at $163.00 by Deutsche Bank www.americanbankingnews.com - March 1 at 7:15 PM
	BIO-TECHNE Corp (TECH) Shares Sold by Rhumbline Advisers www.americanbankingnews.com - March 1 at 7:46 AM
	BIO-TECHNE Corp (TECH) Stake Lifted by Jackson Square Partners LLC www.americanbankingnews.com - February 28 at 3:54 PM
	BIO-TECHNE Corp (TECH) Shares Bought by Hudson Bay Capital Management LP www.americanbankingnews.com - February 27 at 2:58 PM
	BIO-TECHNE Corp (TECH) Holdings Reduced by FDx Advisors Inc. www.americanbankingnews.com - February 27 at 12:17 PM
	BIO-TECHNE Corp (TECH) Shares Bought by American International Group Inc. www.americanbankingnews.com - February 27 at 4:06 AM
	Teacher Retirement System of Texas Has $1.65 Million Stake in BIO-TECHNE Corp (TECH) www.americanbankingnews.com - February 26 at 7:20 AM
	Swiss National Bank Acquires 1,200 Shares of BIO-TECHNE Corp (TECH) www.americanbankingnews.com - February 24 at 5:22 AM
	$163.18 Million in Sales Expected for BIO-TECHNE Corp (TECH) This Quarter www.americanbankingnews.com - February 22 at 5:46 AM
	BIO-TECHNE Corp (TECH) Expected to Announce Earnings of $1.14 Per Share www.americanbankingnews.com - February 20 at 4:08 PM
	Bio-Techne Corporation (TECH) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow seekingalpha.com - February 17 at 8:48 AM
	BIO-TECHNE Corp (TECH) Director Sells $680,300.00 in Stock www.americanbankingnews.com - February 15 at 9:28 PM
	Blog Exposure - AVEO Announced Positive NICE Recommendation for FOTIVDA(R) as First Line Treatment for Advanced Renal Cell Carcinoma finance.yahoo.com - February 14 at 9:19 AM
	BIO-TECHNE Corp (TECH) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - February 13 at 11:04 AM
	BIO-TECHNE (TECH) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - February 10 at 1:30 PM
	BIO-TECHNE Corp (TECH) to Post FY2018 Earnings of $4.07 Per Share, Leerink Swann Forecasts www.americanbankingnews.com - February 9 at 12:28 PM
	Q3 2018 Earnings Forecast for BIO-TECHNE Corp (TECH) Issued By Leerink Swann www.americanbankingnews.com - February 8 at 11:37 AM
	BIO-TECHNE Corp (TECH) Announces $0.32 Quarterly Dividend www.americanbankingnews.com - February 8 at 12:12 AM
	BIO-TECHNE's (TECH) "Buy" Rating Reaffirmed at Craig Hallum www.americanbankingnews.com - February 7 at 1:24 PM
	Bio-Techne Named "Researchers' Choice" by CiteAb finance.yahoo.com - February 7 at 9:23 AM
	BIO-TECHNE's (TECH) "Buy" Rating Reiterated at Robert W. Baird www.americanbankingnews.com - February 7 at 8:36 AM
	What does Bio-Techne Corporation’s (NASDAQ:TECH) Balance Sheet Tell Us About Its Future? finance.yahoo.com - February 6 at 4:16 PM
	BIO-TECHNE (TECH) Issues Earnings Results, Beats Estimates By $0.17 EPS www.americanbankingnews.com - February 6 at 10:02 AM
	Bio-Techne Q2 Profit Beats Estimates; Organic Revenue Up 14% - Quick Facts www.nasdaq.com - February 6 at 9:18 AM
	BRIEF-Bio-Techne Q2 GAAP Earnings Per Share $1.29 www.reuters.com - February 6 at 9:18 AM
	Bio-Techne Releases Second Quarter Fiscal 2018 Results finance.yahoo.com - February 6 at 9:18 AM

Bio-Techne (NASDAQ:TECH) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Bio-Techne (NASDAQ:TECH) Income Statement, Balance Sheet and Cash Flow Statement

Bio-Techne (NASDAQ TECH) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff